Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS).

Poire, Xavier;Graux, Carlos;Ory, Aurélie;Herman, Julie;Beguin, Yves;et.al.
(2022) Bone Marrow Transplantation — Vol. 57, n° 1, p. 116-118 (2022)

Files

PoiréXBoneMarrowTransplant2021.pdf
  • Open Access
  • Adobe PDF
  • 301.31 KB
Download

Details

Authors
  • Poire, Xavierorcid-logoUCLouvain
    Co-first author
  • Graux, CarlosUCLouvain
    Co-first author
  • Ory, Aurélie
    Author
  • Herman, Julie
    Author
  • Beguin, Yves
    Author
Show more
Abstract
(en) TO THE EDITOR: Relapse remains the major cause of failure after allogeneic stem cell transplantation (SCT) and to date, there has been little progress in managing those relapses. Therapeutic options are still limited including supportive care, salvage chemotherapy, donor lymphocyte infusion (DLI), or second SCT. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Poire, X., Graux, C., Ory, A., Herman, J., Baron, F., Schoemans, H., Lewalle, P., De Becker, A., Deeren, D., Berneman, Z., Kerre, T., Zachée, P., Selleslag, D., & Beguin, Y. (2022). Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). Bone Marrow Transplantation, 57(1), 116-118. https://doi.org/10.1038/s41409-021-01464-x (Original work published 2022)